Liraglutide lowered body mass, slowed weight gain and improved health markers in kids ages 6 through 11, according to ...
The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...
In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...
The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.
Liraglutide (Saxenda) added to lifestyle intervention helped reduce BMI in young children with obesity, the phase IIIa SCALE ...
Currently, there are no approved medications for treating nonmonogenic, nonsyndromic obesity in children under 12. While ...
Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the ...
Liraglutide is the first GLP-1 agonist to show benefit in this age group and could provide young patients a much-needed ...
Recently, GLP-1 receptor agonist medications have been prescribed more commonly, in part due to their ability to produce ...